Fifty-five of the U.S. doctors who helped decide what diagnoses and treatments were included in the American Psychiatric Association’s (APA) main diagnostic manual received more than $14 million in undisclosed industry funding, a special report in The BMJ revealed.
According to The BMJ:
“The Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association standardizes symptom criteria and codifies psychiatric disorders. This manual plays a central role in the approval of new psychiatric drugs and the extension of patent exclusivity, and it can influence payers and mental health professionals who seek third party reimbursements.”
The manual, now in its fifth edition, DSM-5-TR, is often referred to as the “bible” of psychiatric disorders. It was released in 2002 and includes changes made since the APA first published the manual in 2013.
The authors of The BMJ report wrote that “industry influence over the development of this diagnostic guideline can have a profound effect on public health (eg, by broadening diagnostic categories and influencing what drugs will be prescribed and covered by insurance). It is thus critical that authors of this psychiatric taxonomy should be free of industry ties.”
Research consistently shows that conflicts of interest lead to “pro-industry thinking and conclusions,” the authors of the report said.
The BMJ found that the doctors who received the most money — often in the form of food, beverages, travel and consulting reimbursements — were those working in diagnostic areas “where drug interventions are often the standard treatment, such as depressive disorders, neurocognitive disorders, and drug induced movement disorders.”
The study’s lead investigator, Lisa Cosgrove, Ph.D., a professor and clinical psychologist in the Applied Ethics Center at the University of Massachusetts, Boston, told Medscape Medical News, the study’s intent was “not to point fingers at the APA or individual members of the APA but rather to provide hopefully a small piece of research data that would help the APA look at the larger systemic issue of conflicts of interest.”
Justine Tanguay, a lawyer with Children’s Health Defense and research director for the organization’s Reform Pharma initiative, praised the researchers for bringing public awareness to the issue.
Tanguay told The Defender:
“It’s an outrageous concept to think that if a doctor, scientist or public health official is paid or funded by Big Pharma that he or she can present or recommend an independent viewpoint.
“It doesn’t take a rocket scientist to understand that even the perception of a conflict of interest undermines the integrity of medicine.”
The Reform Pharma campaign is working “to systematically remove Big Pharma corruption and to restore the healthcare system” — which is needed now more than ever because “such conflicts of interest … have become the norm,” Tanguay said…
Be First to Comment